The cost of Incruse Ellipta can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. While specific price points are not universally fixed, a prescription for Incruse Ellipta typically ranges from approximately $300 to over $400 for a 30-day supply [1].
How can I lower the cost of Incruse?
Individuals seeking to reduce the out-of-pocket expenses for Incruse Ellipta may explore several options. Manufacturer savings cards and patient assistance programs can offer significant discounts, potentially lowering the cost to as little as $10 per prescription for eligible patients [2]. Checking with your insurance provider about coverage tiers and co-pay amounts is also advisable. Comparing prices across different pharmacies can also reveal cost differences.
What is Incruse Ellipta used for?
Incruse Ellipta is a prescription medication used for the long-term maintenance treatment of bronchospasm and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) [3]. It is not indicated for the relief of acute bronchospasm or asthma [3].
How does Incruse Ellipta work?
Incruse Ellipta contains the active ingredient umeclidinium, which is a long-acting muscarinic antagonist (LAMA). Umeclidinium works by relaxing the muscles around the airways in the lungs. This relaxation helps to keep the airways open, making it easier to breathe for individuals with COPD [3].
When does the patent for Incruse expire?
The patent expiration dates for Incruse Ellipta, which contains umeclidinium, are a critical factor in the availability of generic alternatives. Patent information for pharmaceutical drugs is dynamic and can involve multiple patents covering different aspects of the drug, such as the active ingredient, formulation, or method of use. Specific expiry dates can be found on specialized databases [4].
Who makes Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [3]. GSK is a global pharmaceutical company involved in the research, development, manufacturing, and marketing of a broad range of medicines [5].
What are the side effects of Incruse Ellipta?
Common side effects associated with Incruse Ellipta include nasopharyngitis (common cold symptoms), headache, and increased blood pressure [3]. Less common but potentially serious side effects can include paradoxical bronchospasm, urinary retention, and hypersensitivity reactions [3]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Incruse compare to other COPD medications?
Incruse Ellipta is a LAMA and is often used as a maintenance therapy for COPD. Other COPD medications include long-acting beta-agonists (LABAs) and inhaled corticosteroids (ICS), which may be used alone or in combination with LAMAs or LABAs. For instance, combination inhalers containing umeclidinium and vilanterol (a LABA) are also available, offering a dual mechanism of action. The choice of medication depends on the individual patient's symptom severity, exacerbation history, and response to treatment [6].
What are the clinical trial results for Incruse?
Clinical trials for Incruse Ellipta have demonstrated its efficacy in reducing the rate of moderate to severe COPD exacerbations and improving lung function compared to placebo [3][7]. Studies have shown that umeclidinium, as monotherapy or in combination therapies, contributes to symptom relief and disease management in COPD patients [7].
---
Sources:
[1] GoodRx. (n.d.). Incruse Ellipta Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/incruse-ellipta
[2] Incruse Ellipta. (n.d.). Patient Savings Program. Retrieved from https://www.incruse.com/savings-and-support
[3] Incruse Ellipta Prescribing Information. (n.d.). GlaxoSmithKline.
[4] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[5] GlaxoSmithKline. (n.d.). About GSK. Retrieved from https://www.gsk.com/en-gb/about-us/
[6] GOLD COPD Guidelines. (n.d.). Global Initiative for Chronic Obstructive Lung Disease.
[7] D'Urzo, A. D., et al. (2017). Umeclidinium in COPD: A review of the efficacy and safety of a novel long-acting muscarinic antagonist. Therapeutic Advances in Respiratory Disease, 11(4), 153-167.